RxDoctor Payments Data

Elaine Kung, MD

Dermatology · Lincolnshire, ILNPI 1538336649

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $193,148 of the $223,770 with a category attached, or 86.3%. 21 manufacturers reported payments, led by Lumenis BE Inc at 25.7% of the total. Among dermatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$223,770in general payments, 2019–2025

Across 207 payments — averaging $1081.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis BE Inc$58K
  • Incyte Corporation$44K
  • Lumenis BE (hk) Limited$32K
  • Sanofi$31K
  • Sun Pharmaceutical Industries Inc.$17K
  • Lumenis BE ANZ Pty Ltd$15K
  • plus $28K from 15 others

What the payments were for

  • Consulting fees$8,6254%
  • Speaking & faculty fees$193,14886%
  • Travel & lodging$3,0121%
  • Food & beverage$18,7288%
  • Education$2570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$223,770 in reported general payments places this provider in the 95th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$63,420
Medicare patients
189
Services billed
588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab199$736,267
SkyriziRisankizumab-Rzaa34$704,441
StelaraUstekinumab24$321,573
Dupixent SyringeDupilumab54$210,228
OtezlaApremilast36$162,262
RinvoqUpadacitinib12$77,569
Tacrolimus233$33,421
ZoryveRoflumilast14$11,498
Ammonium Lactate359$10,355
Ketoconazole655$8,119
Pimecrolimus34$7,714
Clindamycin Phosphate169$7,543
Betamethasone Dipropionate167$6,344
Clotrimazole390$5,921
Calcipotriene48$5,686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi, Rinvoq$1,192$782,01046 claims
Johnson & JohnsonStelara$177$321,57324 claims
Arcutis Biotherapeutics, Inc.Zoryve$292$11,49814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 606 dermatology providers in Illinois.

Other dermatology in Lincolnshire

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →